Biologically active complex

Details Biologically active complex Biologically active complex

2007-09-11

2010-06-08

Gonzalez, Porfirio Nazario (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C562S899000, C540S001000

Reexamination Certificate

active

07732433

ABSTRACT:
The invention relates to an aqueous solution containing at least one species selected from the group consisting of a 1:1 molar complex of TeO2with a moiety of formula (A) and ammonium salts thereof: HO—X—OH (A); where X is an optionally substituted divalent saturated hydrocarbon group containing 2-8 carbon atoms in the chain connecting the two OH groups; and its use for stimulating cells to produce cytokines and for treating mammalian diseases and conditions responsive to increased production of cytokines. The complex may be used also for treating mammalian cancer which is not responsive to increased production of cytokines.

REFERENCES:
patent: 4752614 (1988-06-01), Albeck et al.
patent: 4761490 (1988-08-01), Albeck et al.
patent: 4929739 (1990-05-01), Sredni et al.
patent: 0194393 (1986-09-01), None
patent: 0333263 (1989-09-01), None
Albeck et al. “Synthesis and Properties of Ammonium Trichloro(Dioxyyethylene-0,0)Tellurate (AS-101). A New Immunomodulating Compound”, Synthesis, p. 635-636, 1989.
Albeck et al. “Tellurium Compounds: Selective Inhibiton of Cysteine Proteases and Model Reaction With Thiols”, Inorganic Chemistry, 37(8): 1704-1712, 1998.
Denney et al. “Preparation and NMR Studies of Tetraalkoxyselenuranes and Tetraalkoxytelluranes”, Journal of the American Chemical Society, 103(9): 2340-2347, 1981.
Gillis et al. “T Cell Growth Factor: Parameters of Production and A Quantitative Microassay for Activity”, The Journal of Immunology, 120(6): 2027-2032, 1978.
Mababazi “Sugar Complexes on Sn(IV), Sb(V), and Te(VI) Hydroxyanions”, Carbohydrate Research, 140: 151-154, 1985.
Pietra et al. “The effects of Carcinogenic Chemicals in Newborn Mice”, Cancer, 14(2): 308-317, 1961.
Uchiyama et al. “A Monoclonal Antibody (Anti-Tac) Reactive With Activated and Functionally Mature Human T Cells. II. Expression of Tac Antigen on Activated Cytotoxic Killer T Cells, Suppressor Cells, and on One of Two Types of Helper T Cells”, The Journal of Immuno.
Communication Pursuant to Article 96(2) EPC Dated Aug. 3, 2007 From the European Patent Office Re.: Application No. 02779867.7.
Official Action Dated Nov. 9, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/496,729.
Response Dated Feb. 7, 2008 to the Communication Pursuant to Article 96(2) EPC of Aug. 3, 2007 From the European Patent Office Re.: Application No. 02779867.7.
Summons to Attend Oral Proceedings Pursuant to Rule 115(1) EPC Dated Mar. 11, 2009 From the European Patent Office Re.: Application No. 02779867.7.
Lima et al. “A Novel Organotellurium Compound (RT-01) as A New Antileishmanial Agent”, Korean Journal of Parasitology, 47(3): 213-218, Sep. 2009.
Persike et al. “Protective Effect of the Organotelluroxetane RF-07 in Pilocarpine-Induced Status Epilepticus”, Neurobiology of Disease, 31: 120-126, 2008.

Affiliated with

Also associated with

Rating

Biologically active complex does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biologically active complex, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biologically active complex will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4168543